The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.

Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French society for oncology pharmacy (SFPO), known as St. Louis' Day. During this event, seven leading experts - comprising medical oncologists and HOPs - engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.